Ross T. Campbell

Ross T. Campbell

Auto-generated profile, based on publicly available information

Ross T. Campbell

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SYSu Ern Yeoh
Su Ern Yeoh
JOJoanna Osmanska
Joanna Osmanska
MPMark C Petrie
Mark C Petrie
KBKatriona J M Brooksbank
Katriona J M Brooksbank
ACAndrew L Clark
Andrew L Clark
RCRoss T Campbell
Ross T Campbell
To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous furosemide. A multi-centre, open-label, randomized, and active-comparator trial. Patients were randomized to dapagliflozin 10 mg once daily or metolazone 5–10 mg once daily for a 3-day treatment period, with follow-up for primary and secondary endpoints until day 5 (96 h). The primary endpoint was a diuretic effect, assessed by change in weight (kg). Secondary endpoints included a change in pulmonary congestion (lung ultrasound), loop diuretic efficiency (weight change per 40 mg of furosemide), and a volume assessment score. 61 patients were randomized. The mean (±standard deviation) cumulative dose of furosemide at 96 h was 977 (±492) mg in the dapagliflozin group and 704 (±428) mg in patients assigned to metolazone. The mean (±standard deviation) decrease in weight at 96 h was 3.0 (2.5) kg with dapagliflozin compared to 3.6 (2.0) kg with metolazone [mean difference 0.65, 95% confidence interval (CI) −0.12,1.41 kg; P = 0.11]. Loop diuretic efficiency was less with dapagliflozin than with metolazone [mean 0.15 (0.12) vs. 0.25 (0.19); difference −0.08, 95% CI −0.17,0.01 kg; P = 0.10]. Changes in pulmonary congestion and volume assessment score were similar between treatments. Decreases in plasma sodium and potassium and increases in urea and creatinine were smaller with dapagliflozin than with metolazone. Serious adverse events were similar between treatments. In patients with heart failure and loop diuretic resistance, dapagliflozin was not more effective at relieving congestion than metolazone. Patients assigned to dapagliflozin received a larger cumulative dose of furosemide but experienced less biochemical upset than those assigned to metolazone. ClinicalTrials.gov Identifier: NCT04860011 ADVOR, Acetazolamide in Decompensated Heart Failure with Volume Overload; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; eGFR, estimated glomerular filtration rate; IV, intravenous.

20 July 2021 in Circulation
Verified
Journal Article
Open access
PDF file
KDKieran F. Docherty
Kieran F. Docherty
RCRoss T. Campbell
Ross T. Campbell
KBKatriona J.M. Brooksbank
Katriona J.M. Brooksbank
JDJohn G. Dreisbach
John G. Dreisbach
PFPaul Forsyth
Paul Forsyth
JMJohn J.V. McMurray
John J.V. McMurray
Background: Patients with left ventricular (LV) systolic dysfunction after myocardial infarction are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin angiotensin system inhibition may result in greater attenuation of adverse LV remodeling as a result of increased levels of substrates for neprilysin with vasodilatory, antihypertrophic, antifibrotic, and sympatholytic effects. Methods: We performed a prospective, multicenter, randomized, double-blind, active-comparator trial comparing sacubitril/valsartan 97/103 mg twice daily with valsartan 160 mg twice daily in patients ≥3 months after myocardial infarction with a LV ejection fraction ≤40% who were taking a renin angiotensin system inhibitor (equivalent dose of ramipril ≥2.5 mg twice daily) and a β-blocker unless contraindicated or intolerant. Patients in New York Heart Association class ≥II or with signs and symptoms of heart failure were excluded. The primary outcome was change from baseline to 52 weeks in LV end-systolic volume index measured using cardiac magnetic resonance imaging. Secondary outcomes included other magnetic resonance imaging measurements of LV remodeling, change in NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity cardiac troponin I, and a patient global assessment of change questionnaire. Results: From July 2018 to June 2019, we randomized 93 patients with the following characteristics: mean age, 60.7±10.4 years; median time from myocardial infarction, 3.6 years (interquartile range, 1.2–7.2); mean LV ejection fraction, 36.8%±7.1%; and median NT-proBNP, 230 pg/mL (interquartile range, 124–404). Sacubitril/valsartan, compared with valsartan, did not significantly reduce LV end-systolic volume index; adjusted between-group difference, –1.9 mL/m 2 (95% CI, –4.8 to 1.0); P =0.19. There were no significant between-group differences in NT-proBNP, high-sensitivity cardiac troponin I, LV end-diastolic volume index, left atrial volume index, LV ejection fraction, LV mass index, or patient global assessment of change. Conclusions: In patients with asymptomatic LV systolic dysfunction late after myocardial infarction, treatment with sacubitril/valsartan did not have a significant reverse remodeling effect compared with valsartan. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03552575.

30 May 2023 in Circulation
Verified
Journal Article
Open access
SYSu Ern Yeoh
Su Ern Yeoh
KDKieran F. Docherty
Kieran F. Docherty
RCRoss T. Campbell
Ross T. Campbell
PJPardeep S. Jhund
Pardeep S. Jhund
AHAnn Hammarstedt
Ann Hammarstedt
JMJohn J.V. McMurray
John J.V. McMurray
Background: ET-1 (endothelin-1) is implicated in the pathophysiology of heart failure and renal disease. Its prognostic importance and relationship with kidney function in patients with heart failure with reduced ejection fraction receiving contemporary treatment are uncertain. We investigated these and the efficacy of dapagliflozin according to ET-1 level in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure). Methods: We investigated the incidence of the primary outcome (cardiovascular death or worsening heart failure), change in kidney function, and the effect of dapagliflozin according to baseline ET-1 concentration, adjusting in Cox models for other recognized prognostic variables in heart failure including NT-proBNP (N-terminal pro-B-type natriuretic peptide). We also examined the effect of dapagliflozin on ET-1 level. Results: Overall, 3048 participants had baseline ET-1 measurements: tertile 1 (T1; ≤3.28 pg/mL; n=1016); T2 (>3.28–4.41 pg/mL; n=1022); and T3 (>4.41 pg/mL; n=1010). Patients with higher ET-1 were more likely male, more likely obese, and had lower left ventricular ejection fraction, lower estimated glomerular filtration rate, worse functional status, and higher NT-proBNP and hs-TnT (high-sensitivity troponin-T). In the adjusted Cox models, higher baseline ET-1 was independently associated with worse outcomes and steeper decline in kidney function (adjusted hazard ratio for primary outcome of 1.95 [95% CI, 1.53–2.50] for T3 and 1.36 [95% CI, 1.06–1.75] for T2; both versus T1; estimated glomerular filtration rate slope: T3, –3.19 [95% CI, –3.66 to –2.72] mL/min per 1.73 m 2 per y, T2, –2.08 [95% CI, –2.52 to –1.63] and T1 –2.35 [95% CI, –2.79 to –1.91]; P =0.002). The benefit of dapagliflozin was consistent regardless of baseline ET-1, and the placebo-corrected decrease in ET-1 with dapagliflozin was 0.13 pg/mL (95% CI, 0.25–0.01; P =0.029). Conclusions: Higher baseline ET-1 concentration was independently associated with worse clinical outcomes and more rapid decline in kidney function. The benefit of dapagliflozin was consistent across the range of ET-1 concentrations measured, and treatment with dapagliflozin led to a small decrease in serum ET-1 concentration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03036124.

31 August 2024 in European Journal of Heart Failure
Verified
Journal Article
Closed access
SMShingo Matsumoto
Shingo Matsumoto
AHAlasdair Henderson
Alasdair Henderson
LSLi Shen
Li Shen
TKToru Kondo
Toru Kondo
MYMingming Yang
Mingming Yang
JMJohn J.V. McMurray
John J.V. McMurray

1 March 2015 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
RCRoss T. Campbell
Ross T. Campbell
CJColette E. Jackson
Colette E. Jackson
AWAnn Wright
Ann Wright
RGRoy S. Gardner
Roy S. Gardner
IFIan Ford
Ian Ford
JMJohn J.V. McMurray
John J.V. McMurray
Aims: The primary aim of this study is to provide data to inform the design of a randomized controlled clinical trial (RCT) of a palliative care (PC) intervention in heart failure (HF). We will identify an appropriate study population with a high prevalence of PC needs defined using quantifiable measures. We will also identify which components a specific and targeted PC intervention in HF should include and attempt to define the most relevant trial outcomes. Methods: An unselected, prospective, near-consecutive, cohort of patients admitted to hospital with acute decompensated HF will be enrolled over a 2-year period. All potential participants will be screened using B-type natriuretic peptide and echocardiography, and all those enrolled will be extensively characterized in terms of their HF status, comorbidity, and PC needs. Quantitative assessment of PC needs will include evaluation of general and disease-specific quality of life, mood, symptom burden, caregiver burden, and end of life care. Inpatient assessments will be performed and after discharge outpatient assessments will be carried out every 4 months for up to 2.5 years. Participants will be followed up for a minimum of 1 year for hospital admissions, and place and cause of death. Methods for identifying patients with HF with PC needs will be evaluated, and estimates of healthcare utilisation performed. Conclusion: By assessing the prevalence of these needs, describing how these needs change over time, and evaluating how best PC needs can be identified, we will provide the foundation for designing an RCT of a PC intervention in HF.

24 July 2025 in European Journal of Heart Failure
Verified
Journal Article
Open access
RCRoss T. Campbell
Ross T. Campbell
MPMark C. Petrie
Mark C. Petrie
KDKieran F. Docherty
Kieran F. Docherty
KBKatriona J.M. Brooksbank
Katriona J.M. Brooksbank
GMGemma McKinley
Gemma McKinley
DLDavid J. Lowe
David J. Lowe
Aims: Echocardiography is a rate-limiting step in the timely diagnosis of heart failure (HF). Automated reporting of echocardiograms has the potential to streamline workflow. The aim of this study was to test the diagnostic accuracy of fully automated artificial intelligence (AI) analysis of images acquired using handheld echocardiography and its interchangeability with expert human-analysed cart-based echocardiograms in a real-world cohort with suspected HF. Methods and results: In this multicentre, prospective, observational study, patients with suspected HF had two echocardiograms: one handheld portable and one cart-based scan. Both echocardiograms were analysed using fully automated AI software and by human expert sonographers. The primary endpoint was the diagnostic accuracy of AI-automated analysis of handheld echocardiography to detect left ventricular ejection fraction (LVEF) ≤40%. Other endpoints included the interchangeability (assessed using individual equivalence coefficient [IEC]), between AI-automated and human analysis of cart-based LVEF. A total of 867 patients participated. The AI-automated analysis produced an LVEF in 61% of the handheld scans and 77% of the cart-based scans, compared to 76% and 77% of human analyses of the handheld and cart-based scans, respectively. The AI-automated analysis of handheld echocardiography had a diagnostic accuracy of 0.93 (95% confidence interval [CI] 0.90, 0.95) for identifying LVEF ≤40% (compared to the human analysis of cart-based transthoracic echocardiography scans). AI-automated analysis of LVEF on handheld devices was interchangeable with cart-based LVEF reported by two expert humans (IEC −0.40, 95% CI −0.60, −0.16). Conclusions: Artificial intelligence-automated analysis of handheld echocardiography had good diagnostic accuracy for detecting LVEF ≤40%. AI-automated analysis of LVEF of handheld scans was interchangeable with cart-based expert human analysis.